Sign in Create account
Sign in and upgrade to a paid plan to export corporate actions as CSV.

Kerala Ayurveda Limited

Healthcare · Pharmaceuticals & Biotechnology

BSE: 530163
₹146.30
▼ -1.30 (-0.88%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
19/100
Weak
Valuation
—/100
Expensive
Momentum
43/100
Neutral

QVM read Mixed signals Quality Weak, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹190 Cr
PE (TTM)
Data unavailable.
Price to Book
12.8
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
0.21%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-63.7
Free Cash Flow
₹-30 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-442.20%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
0.00%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
18.55%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
259.74%
as of June 30, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
28.25%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.45
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
5.43
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-1.85
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
11.77%
as of June 30, 2025
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-23.18%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-19.06%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-7.46%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-18.52%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-28.82%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (5.43)
  • No Return on equity is 15% or more (-28.8%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

1 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (20.4% pledged)

Peer comparison

2 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

0 of 5 met
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.9%
Low 145.0000 · High 152.7500
1W return
-11.1%
Low 145.0000 · High 166.8500
1M return
-15.1%
Low 145.0000 · High 189.0000
52W return
-63.7%
Low 145.0000 · High 214.4000
Lifetime High ₹402.9000 (Dec. 24, 2024)
Lifetime Low ₹17.0500 (Feb. 26, 2009)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
152.6
10D
158.9
20D
168.1
50D
199.1
100D
228.7
200D
261.3

Delivery and volume

Day avg. delivery
76.9%
Week avg. delivery
84.0%
Month avg. delivery
80.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

148.02
Pivot
First resistance151.03
Second resistance155.77
Third resistance158.78
First support143.28
Second support140.27
Third support135.53
Day RSI27.7
Day MFI2.1
Day MACD-13.63
Day MACD signal-13.65

Beta

1M0.01
3M-0.58
1Y-0.58
3Y0.68

Price change analysis

↓ -15.1%
Over 1 Month
LowHigh
145.00189.00
↓ -63.7%
Over 3 Months
LowHigh
145.00214.40
↓ -63.7%
Over 6 Months
LowHigh
145.00214.40
↓ -63.7%
Over 1 Year
LowHigh
145.00214.40
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹23 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹-5.9200

Ranks #120 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter35.61%
  • Mutual funds0.02%
  • FII/FPI0.17%
  • Other DII0.02%
  • Public64.18%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 35.61% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings were unchanged at 0.17% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.02% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 72 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
13 Aug 2026 AUTHUM INVESTMENT & INFRASTRUCTURE LIMITED Bulk Buy 236,201 159.9900 BSE
13 Aug 2026 SANTOSH INDUSTRIES LIMITED Bulk Sell 240,500 159.9700 BSE
24 Mar 2026 NIMISH CHANDULAL SHAH Bulk Sell 100,000 172.4900 BSE
24 Mar 2026 ZAPFIN TEKNOLOGIES PRIVATE LIMITED Bulk Buy 100,000 172.4900 BSE
23 Mar 2026 PRADEEP GHISULAL RATHOD Bulk Buy 150,050 168.9100 BSE
23 Mar 2026 GPR FINANCE CORP Bulk Sell 150,050 168.9000 BSE
3 Sep 2025 KATRA PHYTOCHEM (INDIA) PRIVATE LIMITED Bulk Buy 399 450.5600 BSE
3 Sep 2025 KATRA PHYTOCHEM (INDIA) PRIVATE LIMITED Bulk Sell 274,399 435.3800 BSE
4 Aug 2025 KATRA PHYTOCHEM (INDIA) PRIVATE LIMITED Bulk Sell 200,000 500.4100 BSE
27 Jun 2025 KAMADGIRI EXPORTS PRIVATE LIMITED Bulk Sell 1,061 580.2900 BSE

All bulk and block deals →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Kerala Ayurveda Pharmacy Limited to Kerala Ayurveda Limited

All corporate actions →

Corporate Announcements

All 7 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 AGM/EGM Kerala Ayurveda Ltd - 530163 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
28 Sep 2026 Insider Trading / SAST Kerala Ayurveda Ltd - 530163 - Closure of Trading Window
28 Sep 2026 AGM/EGM Kerala Ayurveda Ltd - 530163 - Shareholder Meeting / Postal Ballot-Outcome of AGM
28 Sep 2026 Company Update Kerala Ayurveda Ltd - 530163 - Summary Of Proceedings Of AGM.
5 Sep 2026 Others Kerala Ayurveda Ltd - 530163 - Reg. 34 (1) Annual Report.
5 Sep 2026 AGM/EGM Kerala Ayurveda Ltd - 530163 - Notice Of 34Th Annual General Meeting Of Kerala Ayurveda Limited
1 Sep 2026 Board Meeting Kerala Ayurveda Ltd - 530163 - Board Meeting Intimation for Preferential Issue Of Shares And Intimation About AGM

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (28.3%)

Weaknesses

  • Low Return on Equity (-28.8%)
  • High financial leverage (Debt/Equity 5.43)
  • Tight liquidity (Current Ratio 0.45)

Opportunities

  • RSI in oversold territory (27.7) -- a technical rebound zone

Threats

  • Down 63.7% over the past year
  • Weak interest coverage (-1.9x) -- limited cushion against rising rates

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Kerala Ayurveda Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.